Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hemant Surgical IndustriesBOM:543916 -0.87%80 EBITDA Margin % is 11.42% as of Mar. 2026, which is 6% below its 10-year median of 12.18. GuruFocus rates BOM:543916 with a GF Score™ of 80/100 and a GF Value™ of ₹332.62 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Hemant Surgical Industries ranks better than 60.74% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Hemant Surgical Industries EBITDA Margin % Related Terms
Hemant Surgical Industries EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:543916 vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Hemant Surgical Industries's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hemant Surgical Industries EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Hemant Surgical Industries's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Hemant Surgical Industries's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hemant Surgical Industries (BOM:543916) has a EBITDA Margin % of 11.42% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Hemant Surgical Industries and its competitors. This is near median its historical median of 12.18. Over the past decade, Hemant Surgical Industries' EBITDA Margin % has ranged from 6.62 to 13.99. According to the industry distribution chart, Hemant Surgical Industries ranks #320 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 39.3%.
Is Hemant Surgical Industries' EBITDA Margin % too high?
Hemant Surgical Industries' current EBITDA Margin % of 11.42% is near median its 10-year median of 12.18. Over the past 10 years, this metric has ranged from a low of 6.62 to a high of 13.99. The Medical Devices & Instruments industry median EBITDA Margin % is 7.52. Hemant Surgical Industries' value of 11.42% is 51.9% above this industry median. Based on the distribution chart, Hemant Surgical Industries ranks #320 out of 815 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Hemant Surgical Industries has a GF Score™ of 80/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hemant Surgical Industries' EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Hemant Surgical Industries ranks #320 out of 815 companies for EBITDA Margin %. This puts Hemant Surgical Industries in the upper half of its industry. The industry median EBITDA Margin % is 7.52. Hemant Surgical Industries' value of 11.42% is 51.9% above this benchmark. Historically, Hemant Surgical Industries' own EBITDA Margin % has ranged from 6.62 to 13.99 over the past decade. While the company's 10-year median is 12.18 vs. the industry median of 7.52, Hemant Surgical Industries has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.52, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hemant Surgical Industries's current EBITDA Margin % of 11.42% is 51.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Hemant Surgical Industries and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hemant Surgical Industries's current EBITDA Margin % is 11.42%, which is near median its own 10-year median of 12.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hemant Surgical Industries stock overvalued right now?
Based on GuruFocus' analysis, Hemant Surgical Industries (BOM:543916) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹332.62, compared to a current price of ₹380.90 — trading 14.5% above its estimated fair value. The current EBITDA Margin % is 11.42%, which is near median its 10-year median of 12.18 and 51.9% above the Medical Devices & Instruments industry median of 7.52. Hemant Surgical Industries' overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Hemant Surgical Industries (BOM:543916), the current EBITDA Margin % is 11.42% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hemant Surgical Industries (BOM:543916) Overvalued in 2026?
Based on GuruFocus' analysis, Hemant Surgical Industries stock appears to be overvalued.
The current stock price of ₹380.90 is trading 14.5% above its estimated GF Value™ of ₹332.62.
GuruFocus considers Hemant Surgical Industries to be Modestly Overvalued.
Key valuation signals for BOM:543916:
EBITDA Margin %: 11.42% (near median its 10-year median of 12.18)
GF Value™: ₹332.62 vs. price of ₹380.90 (14.5% above fair value)
Industry Position: 51.9% above the Medical Devices & Instruments median (#320 of 815)
No single metric tells the full story. See the BOM:543916 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hemant Surgical Industries Ltd is engaged in Importing, manufacturing, and marketing quality surgical and Pharmaceutical Products at an economical price. Its product offerings cover a wide spectrum of equipment and disposables required for (i) Renal Care, (ii) Cardiovascular Disease, (iii) Respiratory Disease, (iv) Critical Care and Radiology, and (v) Surgical disposables. Its products include JMS Meditape, JMS Infusion Set, JMS Scalp Vein Set, Ventilators, ECG Machines, and others.
80GF Score
Get the complete analysis for BOM:543916
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543916 has been successfully added to your 
